We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Company Startup to Launch Genome Information Platform Technology in Japan

By LabMedica International staff writers
Posted on 04 Feb 2014
Print article
Sony Corp. (Tokyo, Japan) reported that Sony, M3, Inc. (Tokyo, Japan), and Illumina, Inc. (San Diego, CA, USA) have agreed to form a collaboration to launch a genome information platform in Japan.

Sony and M3 will establish a new company with Illumina as a minority investor, by the end of February 2014.

Genome research, which analyzes human genetic data together with medical and other information, has the ability to lead to innovations in identifying the origins of diseases, as well as the development of new pharmaceutical agents and treatment approaches. There is mounting anticipation for new developments in the field of personalized medicine, where drugs or treatments are optimized for the individual patient, and this represents an area where genome research findings are forecast to play an increasingly important role.

The new company’s genome-information platform business will provide a genome analysis service for research institutions and businesses in Japan. It will also aggregate genome data with related information such as medical data to support research in areas where genome data is utilized. The company’s goal will be to contribute to advancements in Japanese customized medicine and healthcare. The extent of its business is expected to extend beyond medical research, to provide a service platform that supports the use of genetic data and medical information for personalized medicine and healthcare services for individual patients.

Tadashi Saito, corporate officer, executive vice president, officer in charge of medical business, Sony Corp., noted, “I’m very excited by the potential of this collaboration to deliver new services and breakthroughs that bring us ever closer to the realization of the personalized medicine and healthcare era. At Sony, we are positioning the medical business as one of our key growth pillars. Together with M3, a Sony Group affiliated company and leader in medical information services, and Illumina, who lead the world in next-generation genome-sequencers, we aim to facilitate genome research that further advances Japanese medical care, and in the future establish a new service platform for the medical industry.”

Itaru Tanimura, representative director of M3, Inc., stated, “The Internet had major impact on our lives. Gene diagnosis and treatment will potentially have the same or even greater influence. The current status of the human genome industry is comparable to the Internet in the early 1990s, when companies such as Google, Amazon, and Facebook had yet to emerge. Going forward, I expect companies and services of this magnitude to also appear in this industry. This three party alliance combines each company’s unique strengths and resources, and together we intend to build a service platform that could not have been realized by others.”

“With the cost of whole genome sequencing falling rapidly, the era of genome-based clinical decisions, personalized medicine, and population health initiatives is on the horizon,” said Jay Flatley, chief executive officer of Illumina. Making use of genomic information for these purposes requires significant data collection and analysis and we are excited to work with Sony and M3 to build a powerful genomic database and lay the groundwork to support population health in Japan.”

P5, Inc. (Tokyo, Japan), which will be the new company’s name, launch is scheduled for end of February 2014, with a capital of JPY 118.75 million.

Related Links:

Sony
M3
Illumina


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.